Industry News
Pharmaceutical Industry News
Combining the two drugmakers would…
Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, cost numerous jobs, all while damaging the broader biopharma ecosystem and hurting patients, Angus Liu argues in an editorial.
Novartis’ blockbuster…
Novartis’ blockbuster radioligand therapy Pluvicto has cleared a key milestone on its quest to hit $5 billion in peak sales, securing a U.S. nod in an earlier form of prostate cancer that nearly doubles the
Amylyx’s patient education…
Amylyx’s patient education website aims to empower patients to navigate post-bariatric hypoglycemia (PBH), a rare and often overlooked complication of weight-loss surgery.
A notice from the Health Resources…
A notice from the Health Resources & Services Administration sidelines covered entities' attestations of substantial administrative burden and sets the mulligan program into motion, targeting a Jan. 1 start and 25 potentially eligible products.
A Daiichi Sankyo quarterly report…
A Daiichi Sankyo quarterly report that should have celebrated strong commercial execution was instead derailed by an accounting error and manufacturing losses.
Seven years after it was approved,…
Seven years after it was approved, AbbVie's Skyrizi has proven to be a more-than-adequate replacement for Humira, which was formerly the world's top-selling drug. In the second quarter, the IL-23 inhibitor generated sales of $5.55
Reporting a new miss in one…
Reporting a new miss in one indication, Karyopharm is plowing ahead with plans to advance its XPO1 inhibitor Xpovio in another, despite investors blanching at that dataset back in March.
Shionogi’s “Got the Call, Make…
Shionogi's “Got the Call, Make the Call” campaign for COVID antiviral Xocova kicks off with a TV ad depicting a mother getting a call from her COVID-infected son.
Legend Biotech’s Ying Huang,…
Legend Biotech's Ying Huang, Ph.D., resigned after a six-year stint as CEO. Merck briefly posted—and then quickly deleted—a clinical trial plan to test its PD-1xVEGF bispecific in combination with its TROP2 ADC. The FDA approved
In hopes of challenging Incyte’s…
In hopes of challenging Incyte’s topical JAK inhibitor Opzelura, Pfizer is headed to regulators with results from a pair of late-stage studies testing its would-be oral rival Litfulo in nonsegmental vitiligo.
As self-administered therapies…
As self-administered therapies grow, pharma companies are rethinking how onboarding, training and engagement work together.
In her inaugural earnings call as…
In her inaugural earnings call as the new CEO of Sanofi, Belén Garijo—until recently head honcho at Germany’s Merck KGaA—laid out her ambitions for the French pharma juggernaut, plainly addressing the issues that have tripped
Alnylam’s stock price plummeted…
Alnylam’s stock price plummeted as much as 29% Thursday morning after disappointing Amvuttra sales and a lowered full-year forecast triggered fresh concerns over the ATTR franchise.
In MrBeast’s new “I Helped 100…
In MrBeast's new “I Helped 100 Kids Fight Cancer" YouTube video, Amgen spread its oncology research messaging to a new audience of the channel's over 500 million subscribers.
Worldwide sales of Regeneron and…
Worldwide sales of Regeneron and Sanofi's Dupixent were up again in the second quarter, reaching $6 billion for the first time thanks to a 38% increase.
Despite Robert F. Kennedy Jr….
Despite Robert F. Kennedy Jr. ultimately agreeing to divest referral fees tied to litigation around Merck & Co.’s HPV vaccine Gardasil to win confirmation as Health and Human Services secretary last year, a quartet of
Investors awaiting Bristol Myers…
Investors awaiting Bristol Myers Squibb’s key Alzheimer’s psychosis readout for Cobenfy and atrial fibrillation data for milvexian will have to wait a little longer.
The FDA has rebuked Viatris for a…
The FDA has rebuked Viatris for a direct-to-consumer video that allegedly misled viewers about a cystic fibrosis inhaler.
Eli Lilly has doubled down on its…
Eli Lilly has doubled down on its partnership with CDMO Resilience as the companies plan to invest $750 million to increase production of Lilly’s KwikPen injectable device for its diabetes and obesity medicines Mounjaro and
In pharma, a wall doesn’t just…
In pharma, a wall doesn't just cost money, it stands between a brand and its outcome.